Identifying New Families With Multiple Members Affected by Chordoma - Full Text View

Sponsored by:	National Cancer Institute (NCI)
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00558714

Purpose

RATIONALE: Identifying new families with members affected by chordoma may help the study of chordoma in the future.

PURPOSE: This clinical trial is identifying new families with multiple members affected by chordoma.

Condition	Intervention
Chordoma	Procedure: DNA analysis Procedure: cytology specimen collection procedure Procedure: medical chart review Procedure: questionnaire administration

U.S. FDA Resources

Study Type:	Observational
Official Title:	The Chordoma Family Study: A Pilot Collaboration Between the NCI and Massachusetts General Hospital (MGH) to Identify Multiplex Chordoma Families

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:

Feasibility of conducting a larger study encompassing the remaining English-speaking patients at Massachusetts General Hospital with chordoma [ Designated as safety issue: No ]
Identification of new families with multiple members affected by chordoma to participate in clinical and gene mapping studies [ Designated as safety issue: No ]

Estimated Enrollment:	100
Study Start Date:	June 2003
Estimated Primary Completion Date:	December 2010 (Final data collection date for primary outcome measure)

Detailed Description:

OBJECTIVES:

To determine the feasibility of conducting a larger study encompassing the remaining English-speaking patients at Massachusetts General Hospital with chordoma.
To identify new families with multiple members affected by chordoma to participate in clinical and gene mapping studies.

OUTLINE: Patients complete a questionnaire about demographics (education, marital status, ethnicity, religion, and household income) and family medical history. Buccal cell samples are collected from patients who are 6 years of age and over. DNA from buccal cell samples and previously collected tumor tissue samples will be used for molecular studies. Information about the patient's past medical history is collected from the patient's medical record.

Eligibility

Ages Eligible for Study:	up to 33 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Diagnosed with chordoma at the age of 18 years or younger
Treated with radiation therapy for chordoma at Massachusetts General Hospital between 1988 and the end of the study

PATIENT CHARACTERISTICS:

Speaks English

PRIOR CONCURRENT THERAPY:

See Disease Characteristics

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00558714

Locations

United States, Maryland
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office	Recruiting
Bethesda, Maryland, United States, 20892-1182
Contact: Clinical Trials Office - Warren Grant Magnusen Clinical Center 888-NCI-1937
United States, Massachusetts
Massachusetts General Hospital	Recruiting
Boston, Massachusetts, United States, 02114
Contact: Clinical Trials Office - Massachusetts General Hospital 877-726-5130

Sponsors and Collaborators

National Cancer Institute (NCI)

Investigators

Principal Investigator:

Alisa Goldstein, PhD

NCI - Genetic Epidemiology Branch

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

Study ID Numbers:	CDR0000555674, NCI-03-C-N244
Study First Received:	November 14, 2007
Last Updated:	December 11, 2008
ClinicalTrials.gov Identifier:	NCT00558714
Health Authority:	Unspecified

Keywords provided by National Cancer Institute (NCI):

chordoma

Study placed in the following topic categories:

Neoplasms, Germ Cell and Embryonal
Chordoma

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on January 16, 2009